Infective endocarditis in patients with an implanted transcatheter aortic valve: Clinical characteristics and outcome of a new entity

J Infect. 2015 Jun;70(6):565-76. doi: 10.1016/j.jinf.2014.12.013. Epub 2015 Jan 3.

Abstract

Aims: This study reports one case and review the literature on TAVI-associated endocarditis (TAVIE), to describe its clinical picture and to perform an analysis on prognostic factors.

Methods and results: A MEDLINE search from January 2002 to October 2014 revealed 31 cases of TAVIE, including 1 from our hospital. Median age was 81 years (IQR, 78-85), 53% of patients were males and the median age-adjusted Charlson score was 7 (IQR, 5-8). Heart failure was recorded in 42%, embolic events in 19%, and periannular complications in 45%. The most common causative agent was Enterococcus spp (36%). Ten patients (32%) underwent surgery and nine patients died (29%). The prognostic factors for 6-month mortality were heart failure (HR, 9.97 [3.7-24.5]; p = 0.001), periannular complications (HR, 11.82 [3.3-41.3]; p = 0.004), and nonenterococcal/streptococcal etiology (HR, 4.76 [2.1-11.1]; p = 0.03). In patients with heart failure who did not undergo surgery, mortality was 89% (8 out of 9); in those who did undergo surgery, mortality was 0% (p < 0.001).

Conclusions: TAVIE is an emerging entity with high mortality. Patients with heart failure who did not undergo surgery had a higher probability of dying. Surgical treatment provided better outcomes even in patients in whom surgery had previously been ruled out.

Keywords: Infective endocarditis; Literature review; Outcome; TAVI; Transcatheter aortic valve implantation.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged, 80 and over
  • Anti-Bacterial Agents / administration & dosage*
  • Endocarditis / complications*
  • Endocarditis / drug therapy
  • Endocarditis / mortality
  • Fatal Outcome
  • Female
  • Humans
  • Prognosis
  • Prosthesis-Related Infections / complications*
  • Prosthesis-Related Infections / mortality
  • Risk Factors
  • Staphylococcal Infections / complications*
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / mortality
  • Staphylococcus epidermidis / isolation & purification*
  • Transcatheter Aortic Valve Replacement / adverse effects*

Substances

  • Anti-Bacterial Agents